Concerns:
Dry eye syndrome is a multifactorial disease of the ocular surface characterized by a loss of tear film homeostasis.
The alterations of the tear film cause an increase in its osmolarity which in turn causes chronic inflammation of the conjunctival and corneal tissues.
Possible solution:
Inflammation leads to an increase in tear film alterations triggering a chronic vicious cycle. Relieving this inflammatory process would be of considerable benefit to the patient.
Needs of the medical professional:
To be able to act against all causes leading to dry eye disease.
Eye Pharma’s answer:
At Eye Pharma, we are developing an innovative formula for dry eye therapy to provide adequate and prolonged hydration and counteract the inflammatory process.
ERISnp® is a project for an innovative formulation with a high concentration of polyphenols in combination with hyaluronic acid, which leads to an antioxidant, moisturizing and lubricating effect.
Theory:
Thanks to liposomal technology, the solution remains longer on the ocular surface, prolonging its therapeutic action.